All you need to know about managing hepatitis C virus infection in Australia

What’s new in the September 2018 Consensus Statement?


  • PBS listing of glecaprevir plus pibrentasvir
  • TGA approval of sofosbuvi plus velpatasvir plus voxilaprevir
  • Simplified recommendations for on-treatment monitoring
  • New recommendations for the management of non-responders to DAA therapy
  • New recommendations for the management of HCV in the setting of renal impairment

BROWSE TOPICS


CONTRIBUTORS